News

New treatments show promise in preventing fibrosis in neovascular AMD, addressing a critical need for improved visual outcomes in patients.

Dr. Melissa Yuan discusses the impact of weight and postmenstrual age on foveal maturation in preterm infants, highlighting critical insights for neonatal care.

Dr. J. Peter Campbell discusses the technologies shaping retinopathy of prematurity detection, clinical integration, and global implementation.

Investigators reveal severe ocular injuries from high-pressure water jets used in riots, highlighting risks and the need for preventive measures.

Dr. J. Peter Campbell discusses the technologies shaping retinopathy of prematurity detection, clinical integration, and global implementation.

The SAPPHIRE trial evaluating the VisiPlate is currently underway across several sites across the US, with more site activations scheduled for 2026

K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines.

Kiora Pharmaceuticals advances ocular therapies with new patents for KIO-104, targeting retinal inflammation and enhancing treatment options.

The company noted that this approval marks Celltrion's first Health Canada-approved biologic product in ophthalmology.

Leading cataract surgeons discuss their comprehensive approach to IOL counseling, exploring how they bridge expectation gaps and tailor premium lens strategies to each patient's unique anatomy, goals, and lifestyle.

The company noted that this approval marks Celltrion's first Health Canada–approved biologic product in ophthalmology.

This is the first submission for approval under the exclusive license and commercialization agreement for South Korea that was signed between LENZ and Lotus.

HUC1-394 is a peptide-based eye drop for dry eyes being developed by the company.

The DRAGON trial was a 24-month pivotal phase 3 trial evaluating Tinlarebant in adolescent STGD1 patients.

Kiora Pharmaceuticals advances ocular therapies with new patents for KIO-104, targeting retinal inflammation and enhancing treatment options.

To help with education and awareness, Prevent Blindness is providing free, expert-approved educational resources on GA.

Discover in this case how Dr. Tanit Wongwibulsin digitized his cataract surgery, enhancing efficiency and ensuring precise data management. This transformation allowed him to save time per procedure, nearly doubling his surgical volume. Additionally, the adoption of the digital workflow led to a substantial increase in cases involving premium IOLs.

Researchers analyze the DREAM study, revealing lid margin collarettes in dry eye patients and their surprising lack of progression over time.

The CEO of Dean McGee Eye Institute reflects on the program’s milestones, global partnerships, and the future of patient-centered eye care.

Both therapeutics will leverage AGC Biologics’ BravoAAV suspension platform and use an innovative dual AAV vector approach, which splits the therapeutic gene into 2 halves.

The two meetings will be held concurrently from December 4-7 in Florence, Italy.

Discover cutting-edge retinal technologies and treatments at the FLORetina International Congress in Florence, featuring top exhibitors and expert presentations.

Phakic IOLs deliver a “wow” factor to refractive surgery patients, says Matteo Piovella, MD